| Literature DB >> 26122670 |
Jamila Alessandra Perini1,2, Thais Angeli-Gamba3, Jessica Alessandra-Perini4,5, Luiz Claudio Ferreira6, Luiz Eurico Nasciutti7, Daniel Escorsim Machado8,9.
Abstract
BACKGROUND: Dermal wound healing involves a cascade of complex events including angiogenesis and extracellular matrix remodeling. Several groups have focused in the study of the skin wound healing activity of natural products. The phytomedicine Acheflan®, and its main active constituent is the oil from Cordia verbenacea which has known anti-inflammatory, analgesic and antimicrobial activities. To our knowledge, no investigation has evaluated the effect of Acheflan® in an experimental model of skin wound healing. The present study has explored the wound healing property of Acheflan® and has compared it with topical effectiveness of collagenase and fibrinolysin by using Wistar rat cutaneous excision wound model.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26122670 PMCID: PMC4486146 DOI: 10.1186/s12906-015-0745-x
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Fig. 1The histological evaluation of the skin flaps revealed by HE coloration (10x). Microscopic examination of TC and TAc groups indicated regression of the lesions with better epithelialization (arrows) and more effective re-organization of the dermis (arrowhead) compared to the NC and TF on 8th and 15th days after injury
Fig. 2The evaluation of Picrosirius staining was made to recognize the total density of collagen. In each cut we analyzed the percentage of area occupied by collagen fibers (reddish-yellow). The distribution of collagen was more intense mainly in TC and TAc groups (arrowhead) on 8th and 15th days after injury
Histologic scores of collagen fibers, VEGF and MMP-9 in studied groups
| Score (%) | Group | Day 0 | Day 8 | Day 15 |
|---|---|---|---|---|
| Collagen fibers | NC | 60.3 ± 0.9 | 16.5 ± 1.4 | 59.9 ± 1.6 |
| TC | 60.3 ± 0.9 | 70.6 ± 1.2b, c | 71.3 ± 1.6b, c | |
| TF | 60.3 ± 0.9 | 10.9 ± 1.6b | 20.2 ± 1.4b | |
| TAc | 60.3 ± 0.9 | 68.9 ± 1.2b, c, d | 67.7 ± 0.8b, c, d | |
|
| 1.0 | 0.0001 | 0.0001 | |
| VEGF | NC | 1.5 ± 0.7 | 19.5 ± 2.1 | 2.6 ± 1.0 |
| TC | 1.5 ± 0.7 | 28.2 ± 1.5b, c | 15.5 ± 1.3b, c | |
| TF | 1.5 ± 0.7 | 18.6 ± 0.8 | 12.0 ± 1.2b | |
| TAc | 1.5 ± 0.7 | 26.4 ± 1.8b, c, d | 17.3 ± 1.1b, c, d | |
|
| 1.0 | 0.0001 | 0.0001 | |
| MMP-9 | NC | 0.9 ± 0.8 | 10.2 ± 0.9 | 8.3 ± 1.1 |
| TC | 0.9 ± 0.8 | 47.8 ± 1.9b, c | 10.8 ± 1.9b | |
| TF | 0.9 ± 0.8 | 11.9 ± 1.4b | 10.9 ± 1.7b | |
| TAc | 0.9 ± 0.8 | 17.1 ± 0.8b, c, d | 11.4 ± 0.6b | |
|
| 1.0 | 0.0001 | 0.001 | |
NC is negative control, TC is treated topically with Collagenase ointment, TF is treated topically with Fibrinolysin and TAc is treated topically with phytomedicine cream Acheflan. Day zero, 8th and 15th days after injury. Values are mean ± standard deviations. aAnova test. bSignificant difference when compared to NC group (Student t test, P < 0.05). cSignificant difference when compared to TF group (Student t test, P < 0.05). dSignificant difference when compared to TC group (Student t test, P < 0.05)
Hydroxyproline levels in wound areas of the all treatment groups
| Group | Day 0 | Day 8 | Day 15 |
|---|---|---|---|
| NC | 66 ± 8.3 | 67 ± 5.3 | 115 ± 2.7 |
| TC | 63 ± 1.9 | 86 ± 0.8b, c | 122 ± 2.2 |
| TF | 59 ± 1.6 | 65 ± 1.3 | 120 ± 5.7 |
| TAc | 64 ± 2.7 | 107 ± 9.1b, c, d | 127 ± 10.5 |
|
| 0.087 | 0.0001 | 0.206 |
NC is negative control, TC is treated topically with Collagenase ointment, TF is treated topically with Fibrinolysin and TAc is treated topically with phytomedicine cream Acheflan. Day zero (n = 6), 8th (n = 3) and 15th (n = 3) days after injury. Values are mean ± standard deviation from six animals in each group at day zero and three animals in each group at 8th and 15th days after injury. aAnova test. bSignificant difference when compared to NC group (Student t test, P < 0.05). cSignificant difference when compared to TF group (Student t test, P < 0.05). dSignificant difference when compared to TC group (Student t test, P < 0.05)
Fig. 3Photomicrograph from immunostained with an antibody against VEGF in control and treated groups. The dermis in both groups exhibits positive VEGF immunostaining (arrows); in TC and TAc the immunoreaction is higher, especially in day 8 (arrowheads)
Fig. 4Immunohistochemical staining with MMP-9 in control and treated groups. The pattern of distribution of the MMP-9 staining is similar as with the VEGF study, but anti–MMP-9 antibody immunoreactivity was more intense in TC on day 8 (arrows); on the day 15, the immunoreactions were reduced and no differences were observed among the treated groups (arrowheads)